Drugs that contain Infigratinib Phosphate

1. List of Truseltiq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9067896 HELSINN HLTHCARE Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
Aug, 2028

(5 years from now)

US8552002 HELSINN HLTHCARE Compounds and compositions as protein kinase inhibitors
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278969 HELSINN HLTHCARE Pharmaceutical dosage forms
Dec, 2034

(11 years from now)

US11160804 HELSINN HLTHCARE Pharmaceutical dosage forms
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic